Skip to main content

Advertisement

Table 1 Action potential (AP) parameters of pulmonary vein cardiomyocytes treated with or without (control) arginine vasopressin (AVP) and/or AVP receptor antagonist (V1,OPC 21268 and V2 OPC 41061)

From: Arginine vasopressin modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes

  APA (mV) APD75 (msec) APD50 (msec) APD20 (msec) Beating rate interval (msec) EDD (mV/msec) LDD (mV/msec) MDP (mV) TP (mV)
Control, (n = 12) 80 ± 6 140 ± 13 99 ± 13 54 ± 8 453 ± 28 0.13 ± 0.05 0.21 ± 0.04 −55 ± 4 −39 ± 3
AVP (0.1 μM), (n = 11) 82 ± 8 164 ± 18 109 ± 16 65 ± 11 432 ± 35# 0.08 ± 0.01 0.33 ± 0.05# −60 ± 2 −32 ± 5
AVP (1 μM), (n = 13) 71 ± 7 121 ± 12 82 ± 8 43 ± 5 305 ± 21* 0.09 ± 0.01 0.43 ± 0.06* −53 ± 3 −32 ± 2
AVP (1 μM) + OPC 21268 (0.1 μM), (n = 11) 80 ± 6 131 ± 8 91 ± 7 48 ± 4 813 ± 213# 0.08 ± 0.01 0.25 ± 0.03# −56 ± 4 −36 ± 3
AVP (1 μM) + OPC 41061 (10 nM), (n = 12) 90 ± 4 142 ± 4 104 ± 3 58 ± 4 329 ± 22* 0.11 ± 0.02 0.37 ± 0.02* −54 ± 5 −36 ± 3
OPC 21268 (0.1 μM), (n = 10) 90 ± 4 148 ± 13 97 ± 10 57 ± 8 581 ± 100 0.09 ± 0.02 0.29 ± 0.03 −62 ± 3 −34 ± 3
OPC 41061 (10 nM), (n = 10) 94 ± 4 158 ± 9 118 ± 8 70 ± 5 468 ± 52§ 0.09 ± 0.01 0.24 ± 0.04§ −59 ± 2 −30 ± 3
  1. APD75, APD50, and APD20 = AP duration at 75, 50 and 20% repolarization of the amplitude, EDD Early diastolic depolarization, LDD Late diastolic depolarization, MDP Maximum diastolic potential, TP Threshold potential. * P < 0.05 vs Control, # P < 0.05 vs AVP (1 μM), § P < 0.05 OPC 41461 (10 nM) vs AVP (1 μM) + OPC 41461 (10 nM),